This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Keitel, W. A. Articles by Couch, R. B. Search for Related Content PubMed PubMed Citation Articles by Keitel, W. A. Articles by Couch, R. B.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, 09 1996, 507-510, Vol 3, No. 5
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly

WA Keitel, TR Cate, RL Atmar, CS Turner, D Nino, CM Dukes, HR Six and RB Couch
Department of Microbiology and Immunology, Baylor College of Medicine Houston, Texas 77030, USA.

The reactogenicities and immunogenicities of two influenza virus vaccines were compared in a placebo-controlled clinical trial among healthy ambulatory persons > or = 65 years old (mean age, 72 years). Volunteers were assigned randomly to receive 15-, 45-, or 135- micrograms doses of monovalent influenza A/Taiwan (H1N1) hemagglutinin (HA) or subvirion (SV) vaccine intramuscularly or a placebo. Increasing doses of SV vaccine were associated with a higher rate of injection site discomfort (P < 0.05; chi-square test for linear trend), but all doses of both vaccines were well tolerated. Increasing the dose of the HA or the SV vaccine resulted in increasingly higher postimmunization levels of serum hemagglutination inhibition and neutralizing antibody levels (P < 0.001; multiple linear regression). Mean serum antibody titers at 1 month increased two- to threefold with a ninefold increase in dose; the frequencies of fourfold or greater rises in titer likewise increased. An increase in the dose of the HA or the SV vaccine also resulted in increased frequencies of rises in immunoglobulin A or G antibody titers in nasal wash specimens. The frequencies increased approximately twofold for each vaccine with a ninefold increase in the dose. These data suggest that increasing the HA vaccine dose is a promising approach to the development of improved influenza virus vaccines for use in elderly people.

This article has been cited by other articles:

• Keitel, W. A., Atmar, R. L., Cate, T. R., Petersen, N. J., Greenberg, S. B., Ruben, F., Couch, R. B. (2006). Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons.. Arch Intern Med 166: 1121-1127 [Abstract] [Full Text]  
• Kenney, R. T., Frech, S. A., Muenz, L. R., Villar, C. P., Glenn, G. M. (2004). Dose Sparing with Intradermal Injection of Influenza Vaccine. NEJM 351: 2295-2301 [Abstract] [Full Text]